These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29369916)

  • 1. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
    Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
    Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Cardiol; 2017 Jul; 120(1S):S28-S36. PubMed ID: 28606341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.
    Ahmed HM; Khraishah H; Cho L
    Eur Heart J; 2018 Jul; 39(25):2368-2375. PubMed ID: 29236983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.
    Wu L; Gunton JE
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
    Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
    J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.